Mirum Pharmaceuticals, Inc. (MIRM) names Lon Cardon to board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
December 19, 2022 8:30 AM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in drug discovery and development.
Dr. Cardon currently serves as president and chief executive officer of The Jackson Laboratory. Prior to this role, Dr. Cardon was chief scientific officer and chief scientific strategy officer at BioMarin. Before joining BioMarin, he was a... More
